Exelixis Inc. (EXEL)
EXEL or TECH: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Exelixis (EXEL) and Techne (TECH). But which of these two stocks is more attractive to value investors?
Why Exelixis Stock Trounced the Market on Thursday
Cancer drug specialist Exelixis (EXEL 5.02%) was quite the stock market star on Friday. Following news that it's making a big, shareholder-pleasing move, market players piled into the company to push its shares 5% higher on the day.
Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday?
On Friday, Exelixis, Inc. EXEL authorized repurchasing up to an additional $500 million of the company's common stock before December 31, 2025.
Is Exelixis (EXEL) a Solid Growth Stock? 3 Reasons to Think "Yes"
Exelixis (EXEL) could produce exceptional returns because of its solid growth attributes.
Exelixis Gains 6.7% Post Q4 Earnings: Is This the Right Time to Buy?
EXEL stock gains on the back of encouraging performance of its lead drug Cabometyx and impressive pipeline progress. We are optimistic about the stock as we believe there is room for further growth.
International Markets and Exelixis (EXEL): A Deep Dive for Investors
Explore Exelixis' (EXEL) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
EXEL Tops Q4 Earnings and Sales, Cabometyx Label Expansion in Focus
Exelixis beats on Q4 earnings and sales as lead drug Cabometyx maintains momentum. The company reiterates its guidance for 2025.
Exelixis: Cabozantinib Continues To Grow, Zanzalintinib Could Soon Follow
Exelixis reported $515.2M in net product revenues in Q4'24, a 20% increase over net product revenues for Q4'23. EXEL's 2025 total revenue guidance is flat at $2.15B-$2.25B, although that doesn't model potential approval of cabozantinib for neuroendocrine tumors. EXEL's STELLAR-303 trial of zanzalintinib in metastatic colorectal cancer is expected to produce a result in H2'25, but the outcome is challenging to predict.
Exelixis, Inc. (EXEL) Q4 2024 Earnings Call Transcript
Exelixis, Inc. (NASDAQ:EXEL ) Q4 2024 Earnings Conference Call February 11, 2025 5:00 PM ET Company Participants Susan Hubbard - Executive Vice President, Public Affairs & Investor Relations Mike Morrissey - President & Chief Executive Officer Chris Senner - Chief Financial Officer PJ Haley - Executive Vice President, Commercial Amy Peterson - Chief Medical Officer Dana Aftab - Chief Scientific Officer Conference Call Participants Asthika Goonewardene - Truist Sean Laaman - Morgan Stanley David Lebowitz - Citi Gregory Renza - RBC Capital Markets Eva Fortea-Verdejo - Wells Fargo Jason Gerberry - Bank of America Securities Andy Hsieh - William Blair Yaron Werber - TD Cowen Peter Lawson - Barclays Stephen Willey - Stifel Ash Verma - UBS Sudan Loganathan - Stephens Operator Good day, ladies and gentlemen, and welcome to the Exelixis Fourth Quarter and Fiscal Year 2024 Financial Results Conference Call. My name is Sherry, and I'll be your operator for today.
Exelixis (EXEL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Exelixis (EXEL) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Exelixis (EXEL) Q4 Earnings and Revenues Top Estimates
Exelixis (EXEL) came out with quarterly earnings of $0.55 per share, beating the Zacks Consensus Estimate of $0.51 per share. This compares to earnings of $0.33 per share a year ago.
